HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

62.000

-1.200-1.90%

Volume:1.11M

Turnover:68.57M

Market Cap:12.34B

PE:-43.85

High:63.300

Open:63.200

Low:61.000

Close:63.200

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.53

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.414

ROE:-51.55%

ROA:-12.87%

PB:11.34

PE(LYR):-43.85

PS:49.52

Loading ...

Overview Company News Filings

Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published

LEADS BIOLABS-B (09887) Triggers Option Exercise to Secure LBL-051 License

Nanjing Leads Biolabs Says Oblenio Exercises LBL-051 License Option, Triggering USD 10 Million Fee

Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation

Bulletin Express

Nanjing Leads Biolabs Schedules Board Meeting to Review Interim Results, Dividend Recommendation

Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum

Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment

Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

THOMSON REUTERS

Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase

Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage

Bulletin Express

LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage

Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases

THOMSON REUTERS

Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction

Bulletin Express

Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

THOMSON REUTERS

LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total

Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/09887/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":62,"timestamp":1789027724007,"preClose":63.2,"halted":0,"volume":1112700,"delay":0,"changeRate":-0.018987341772151944,"floatShares":198000000,"shares":199000000,"eps":-1.4140828968415768,"marketStatus":"Closed","change":-1.2,"latestTime":"09-10 16:08:44","open":63.2,"high":63.3,"low":61,"amount":68573175,"amplitude":0.036392,"askPrice":62,"askSize":2000,"bidPrice":61.95,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.6093104803813945,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":63.2,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.527291,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.413958,"volumeRatio":0.527291,"shares":199000000,"dividePrice":0,"high":63.3,"amplitude":0.036392,"preClose":63.2,"low":61,"week52Low":44.72,"pbRate":"11.34","psRate":"49.52","week52High":97.5,"institutionHeld":0,"latestPrice":62,"committee":-0.666667,"eps":-1.4139579559800206,"divideRate":0,"volume":1112700,"delay":0,"ttmEps":-1.6091682902464457,"open":63.2,"prevYearClose":51,"prevWeekClose":64,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":67.7,"twentyDayClose":69.15,"sixtyDayClose":55.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-09","current":-38.501919,"percent":0.554348,"low":-76.458084,"twenty":-45.565149,"median":-39.965338,"eighty":-34.758603,"high":-30.202688,"avg":-42.101948,"sd":9.707299,"marketCap":12331685120},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-09","current":-39.527571,"twenty":-45.565149,"median":-39.965338,"eighty":-34.758603,"marketCap":12331685120}],"updateTime":1789030062036},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143205687","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","url":"https://stock-news.laohu8.com/highlight/detail?id=1143205687","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143205687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:58","pubTimestamp":1787194735,"startTime":"0","endTime":"0","summary":"On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198582483","title":"LEADS BIOLABS-B (09887) Triggers Option Exercise to Secure LBL-051 License","url":"https://stock-news.laohu8.com/highlight/detail?id=1198582483","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198582483?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:44","pubTimestamp":1787179452,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that Oblenio Bio, Inc. (NewCo) has officially exercised its option to retain the exclusive license for LBL-051, marking a significant step forward in their...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660769234","title":"Nanjing Leads Biolabs Says Oblenio Exercises LBL-051 License Option, Triggering USD 10 Million Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2660769234","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660769234?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:16","pubTimestamp":1787177768,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Oblenio exercises LBL-051 license option, triggering USD 10 million feeOblenio exercised its option to retain the worldwide license for LBL-051, triggering a one-time US$ 10","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL3gmbQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161859865","title":"Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation","url":"https://stock-news.laohu8.com/highlight/detail?id=1161859865","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161859865?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:28","pubTimestamp":1787135308,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes: 1. Reviewing and approving the interim financial results of Leads...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660384444","title":"Nanjing Leads Biolabs Schedules Board Meeting to Review Interim Results, Dividend Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660384444","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660384444?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:11","pubTimestamp":1787134271,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs schedules board meeting to review interim results, dividend recommendationNanjing Leads Biolabs will hold a board meeting on Aug. 31, 2026.Directors are set to review interim res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL9sLqRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000500386.USD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114260368","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1114260368","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114260368?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:55","pubTimestamp":1786931757,"startTime":"0","endTime":"0","summary":"On August 17, LEADS BIOLABS-B rose 5.18% in regular trading, trading at HK$76.95/share, with turnover of HK$64.37 million.The rise extends recent momentum fueled by a series of clinical milestones....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Dense Pipeline Catalysts Continue to Drive Momentum","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145060311","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1145060311","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145060311?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:24","pubTimestamp":1786688645,"startTime":"0","endTime":"0","summary":"On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.The movement was driven by a cluster of recent positive developments. On August...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises, Multiple Pipeline Catalysts Drive Positive Sentiment","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657509468","title":"Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657509468","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657509468?lang=en_us&edition=fundamental","pubTime":"2026-08-06 12:57","pubTimestamp":1785992261,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads Biolabs jumps on progress of tumor antibody treatment** Shares of Nanjing Leads Biolabs9887.HKjump 8.3% to HK$62.85, the highest level since July 24** Stock of the China-based oncology therapies developer set for the biggest one-day pct gain since July 15** Company says Phase II clinical study evaluating its bispecific antibody PD-L1/4-1BB and Opamtistomig  for treatment of first-line hepatocellular carcinoma , or malignant tumor, has completed safety run in phase assessment review and has successfully entered expansion phase** Preliminary data show that Opamtistomig in combination with bevacizumab has demonstrated encouraging efficacy signals in patients with HCC with a favorable overall safety profile and good tolerability - co** YTD, stock up 23.1%, Hang Seng Biotech Index.HSBIOup 1.5%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N443044:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161568880","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1161568880","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161568880?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:55","pubTimestamp":1785984951,"startTime":"0","endTime":"0","summary":"On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657604570","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2657604570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657604570?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:53","pubTimestamp":1785977613,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUABKLW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572869","title":"Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572869?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:00","pubTimestamp":1785970810,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Phase II Opamtistomig trial in first-line liver cancer enters expansion phaseNanjing Leads Biolabs reported its Phase II study of LBL-024 (opamtistomig) for first-line hepat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4Rzf09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131250364","title":"Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131250364","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131250364?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:25","pubTimestamp":1785968734,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has completed the safety run-in of a Phase II study in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193898777","title":"LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1193898777","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193898777?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:20","pubTimestamp":1785968415,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that its independently developed PD-L1/4-1BB bispecific antibody, Opatsosumimab (Vilitis™), has successfully completed the safety run-in assessment in a Phase II...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055321","title":"Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656055321?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:56","pubTimestamp":1785844585,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA5J5NW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252160.HKD","HK0000252152.HKD","09887","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152365137","title":"Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=1152365137","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152365137?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:24","pubTimestamp":1785842650,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that Oblenio Bio, its NewCo partner formed with Aditum Bio, has administered first doses to patients in a European Phase Ia, first-in-human...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656853074","title":"Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2656853074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656853074?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:10","pubTimestamp":1785841828,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs clarifies award grant to executive director is exempt connected transaction under HK rulesNanjing Leads Biolabs issued a supplemental clarification on its July 1, 2026 award gran","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL1LdRlk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342024","title":"Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656342024?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:43","pubTimestamp":1785728605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA6LLSYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","09887","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122893332","title":"LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1122893332","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122893332?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:32","pubTimestamp":1785724340,"startTime":"0","endTime":"0","summary":"Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.On August 3, the company announced that China's National Medical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IND","BK4588","09887","VXUS","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","KCAI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168072852","title":"LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total","url":"https://stock-news.laohu8.com/highlight/detail?id=1168072852","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168072852?lang=en_us&edition=fundamental","pubTime":"2026-08-03 08:50","pubTimestamp":1785718227,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on July 31, LEADS BIOLABS-B (09887) experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","BK1161","161027","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656456073","title":"Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656456073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656456073?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:05","pubTimestamp":1785708356,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nFWN43Z00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","09887","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":133,"code":"91000000","status":"200"}]}}